Rallybio Corporation

NASDAQ:RLYB

1.13 (USD) • At close September 13, 2024
Bedrijfsnaam Rallybio Corporation
Symbool RLYB
Munteenheid USD
Prijs 1.13
Beurswaarde 46,880,988
Dividendpercentage 0%
52-weken bereik 1.08 - 5.15
Industrie Biotechnology
Sector Healthcare
CEO Dr. Stephen Uden M.B, M.D.
Website https://www.rallybio.com

An error occurred while fetching data.

Over Rallybio Corporation

Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal

Vergelijkbare Aandelen

Praxis Precision Medicines, Inc. logo

Praxis Precision Medicines, Inc.

PRAX

59.88 USD

Adicet Bio, Inc. logo

Adicet Bio, Inc.

ACET

1.49 USD

Day One Biopharmaceuticals, Inc. logo

Day One Biopharmaceuticals, Inc.

DAWN

14.13 USD

Alpha Tau Medical Ltd. logo

Alpha Tau Medical Ltd.

DRTS

2.34 USD

Vaxart, Inc. logo

Vaxart, Inc.

VXRT

0.987 USD

Kinnate Biopharma Inc. logo

Kinnate Biopharma Inc.

KNTE

2.65 USD

CareMax, Inc. logo

CareMax, Inc.

CMAX

2.04 USD

Bionano Genomics, Inc. logo

Bionano Genomics, Inc.

BNGO

0.43 USD

IRadimed Corporation logo

IRadimed Corporation

IRMD

48.47 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)